Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.2484
+0.00461.89%
Post-market: 0.2420-0.0064-2.58%19:07 EDT
Volume:712.52K
Turnover:177.16K
Market Cap:11.02M
PE:-0.15
High:0.2520
Open:0.2450
Low:0.2401
Close:0.2438
52wk High:5.14
52wk Low:0.1980
Shares:44.38M
Float Shares:41.42M
Volume Ratio:0.73
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6559
EPS(LYR):-1.8303
ROE:-166.46%
ROA:-83.21%
PB:0.45
PE(LYR):-0.14

Loading ...

Vistagen Therapeutics Says Fasedienol Clinical Program Exceeds ICH Exposure Thresholds

MT Newswires Live
·
Jun 10

Vistagen announces fasedienol achieves minimum patient exposures

TIPRANKS
·
Jun 09

Vistagen Achieves Minimum Ich Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Jun 09

Vistagen Therapeutics - Topline Results From Palisade-4 Phase 3 Trial Expected in Q2 2026

THOMSON REUTERS
·
Jun 09

VistaGen says fasedienol SAD program meets ICH E1 minimum long-term safety exposure thresholds

Reuters
·
Jun 09

VistaGen to join Jefferies Global Healthcare Conference, hosts investor meetings

Reuters
·
May 27

VistaGen files initial beneficial ownership statement for Chief Medical Officer Angel S. Angelov

Reuters
·
May 20

BRIEF-Vistagen Appoints Angel S. Angelov As Chief Medical Officer

Reuters
·
May 19

VistaGen appoints Angel Angelov as chief medical officer

Reuters
·
May 19

Vistagen Appoints Angel S. Angelov, Md, MBA, as Chief Medical Officer

THOMSON REUTERS
·
May 19

VistaGen reports positive fasedienol data in PALISADE-3 open-label extension study

Reuters
·
May 12

Vistagen Therapeutics Inc - Palisade-4 Topline Data Expected in Q2 2026

THOMSON REUTERS
·
May 12

Vistagen Therapeutics Inc - Fasedienol Nasal Spray Well-Tolerated With No New Safety Findings After 12 Months

THOMSON REUTERS
·
May 12

Vistagen Therapeutics Inc - No Serious Adverse Events Related to Fasedienol Reported

THOMSON REUTERS
·
May 12

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of Palisade-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
May 12

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), VistaGen Therapeutics (VTGN) and Prime Medicine, Inc. (PRME)

TIPRANKS
·
May 09

BRIEF-Vistagen Announces Completion Of Last Patient Visit In Palisade-4 Phase 3 Public Speaking Challenge Study Of Fasedienol For Acute Treatment Of Social Anxiety Disorder

Reuters
·
May 08

VistaGen completes last patient visit in PALISADE-4 Phase 3 fasedienol trial

Reuters
·
May 08

Vistagen Therapeutics Inc - Open Label Extension of Palisade-4 Study Remains Ongoing

THOMSON REUTERS
·
May 08

Vistagen Therapeutics Inc - Topline Results for Palisade-4 Randomized Portion Expected in Q2 2026

THOMSON REUTERS
·
May 08